Cargando…

A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer

BACKGROUND: Germline genetic polymorphisms in certain genes are associated with the response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer (BC). This translational study aims to evaluate the potential role of rs1042713 in the beta 2-adrenergic receptor (ADRB2) gene in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Yueyao, Yan, Tingting, Zhou, Liheng, Yin, Wenjin, Lu, Jinsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267711/ https://www.ncbi.nlm.nih.gov/pubmed/30568487 http://dx.doi.org/10.2147/BCTT.S189197

Ejemplares similares

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis
por: Jiang, Yiwei, et al.
Publicado: (2012)

HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer
por: Dai, Huijuan, et al.
Publicado: (2021)

Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials
por: Xu, Yaqian, et al.
Publicado: (2021)

Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
por: Bayarmaa, Battseren, et al.
Publicado: (2019)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study
por: Zhou, Liheng, et al.
Publicado: (2017)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer
por: Hjorth, Cathrine F., et al.
Publicado: (2023)

Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival
por: Matsuo, Koji, et al.
Publicado: (2019)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019)

Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting
por: Wu, Ziping, et al.
Publicado: (2018)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy
por: Wu, Ziping, et al.
Publicado: (2019)

Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer
por: Wang, Yaohui, et al.
Publicado: (2018)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
por: Wan, Caifeng, et al.
Publicado: (2023)

Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
por: Dai, Huijuan, et al.
Publicado: (2021)

LncRNA MIR205HG expression predicts efficacy of neoadjuvant chemotherapy for patients with locally advanced breast cancer
por: Xu, Yaqian, et al.
Publicado: (2021)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark
por: Hjorth, Cathrine F., et al.
Publicado: (2022)

Genetic polymorphisms of GGT1 gene (rs8135987, rs5751901 and rs2017869) are associated with neoadjuvant chemotherapy efficacy and toxicities in breast cancer patients
por: Sun, Lu, et al.
Publicado: (2023)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
por: Lankester, K J, et al.
Publicado: (2005)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2018)

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
por: Lee, Hee Jin, et al.
Publicado: (2015)

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer
por: Song, Xiao, et al.
Publicado: (2017)

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer
por: Pölcher, Martin, et al.
Publicado: (2010)

Biological Markers and Response to Neoadjuvant Taxane-Based Chemotherapy in Patients with Locally Advanced Breast Cancer
por: El-sayed, Mohamed I., et al.
Publicado: (2012)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC
por: Brodie, Seth A., et al.
Publicado: (2014)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy
por: Sha, Rui, et al.
Publicado: (2021)

Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review
por: Asiri, Mohamed S, et al.
Publicado: (2023)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer
por: Kallarackal, Jim, et al.
Publicado: (2020)

Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy
por: Nicosia, Luca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j0gvpppjtvi30guh5ll0af1n5a